Showing results (121-130 of 165) with videos related to

Sort By:
Pageof 17
Health & Justice|March 31, 2025
The importance of contextually specific support relationships in implementing programs to link people to medication for opioid use disorder (MOUD) treatment during reentry from county jailsMargaret McGladrey, Marisa Booty, Susannah Stitzer, et al.
Frontiers in Public Health|March 1, 2024
The development of a recovery coaching training curriculum to facilitate linkage to and increase retention on medications for opioid use disorderTrevor Moffitt, Amanda Fallin-Bennett, Laura Fanucchi, et al.
Journal of Addiction Medicine|April 7, 2025
Dosing to Effect With Weekly and Monthly Subcutaneous and Daily Sublingual Buprenorphine: Post Hoc Analysis of a Phase 3 Clinical TrialMichelle R Lofwall, Edward V Nunes, Sharon L Walsh, et al.
Journal of Substance Use and Addiction Treatment|January 1, 2025
Description of implementing a mail-based overdose education and naloxone distribution program in community supervision settings during COVID-19Carrie B Oser, Margaret McGladrey, Douglas R Oyler, et al.
Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine|July 28, 2023
Early emergency department experience with 7-day extended-release injectable buprenorphine for opioid use disorderGail D'Onofrio, Jeanmarie Perrone, Kathryn F Hawk, et al.
Drug and Alcohol Dependence|October 22, 2020
Operationalizing and selecting outcome measures for the HEALing Communities StudySvetla Slavova, Marc R LaRochelle, Elisabeth D Root, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|December 29, 2015
Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked CannabisMargaret Haney, Robert J Malcolm, Shanna Babalonis, et al.
Health & Justice|June 27, 2024
Rapid jail-based implementation of overdose education and naloxone distribution in response to the COVID-19 pandemicCarrie B Oser, Margaret McGladrey, Marisa Booty, et al.
JAMA Psychiatry|June 28, 2017
Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder: A Randomized Clinical TrialSharon L Walsh, Sandra D Comer, Michelle R Lofwall, et al.
Addiction Biology|June 27, 2019
A randomized, double-blind, placebo-controlled study of the kappa opioid receptor antagonist, CERC-501, in a human laboratory model of smoking behaviorJermaine D Jones, Shanna Babalonis, Ronald Marcus, et al.
Pageof 17